Achilles Therapeutics Plc (ACHL) ADR EACH REPR 1 ORD SHS SPON

Sell:$1.10Buy:$1.14$0.01 (0.44%)

Prices delayed by at least 15 minutes
Sell:$1.10
Buy:$1.14
Change:$0.01 (0.44%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.10
Buy:$1.14
Change:$0.01 (0.44%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Achilles Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company has been developing artificial intelligence (AI)-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has used DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.

Key people

Iraj Leo Kiryakos Keverian Ali
Chief Executive Officer, Executive Director
Robert William Coutts
Chief Financial Officer
Sergio Quezada
Chief Scientific Officer
Karl Peggs
Chief Medical Officer
Edwin Moses
Non-Executive Independent Chairman of the Board
Carsten Boess
Non-Executive Independent Director
Bernhard Ehmer
Non-Executive Independent Director
Michael F. Giordano
Non-Executive Independent Director
Julie O'Neill
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00449L1026
  • Market cap
    $46.85m
  • Employees
    204
  • Shares in issue
    0.00
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.